Clinical trial
A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
NCT07372625 is registered in ClinicalTrials.gov with PMV Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
- Lead sponsor
- PMV Pharmaceuticals, Inc
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 4, 2026
- Completion date
- January 31, 2028
- Enrollment
- 14 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors, tp53 y220c mutation